Targeting the epithelial cells in fibrosis: a new concept for an old disease

Solange Moll1, Lyubov Chaykovska, Matthias Meier

  • 1Institute of Clinical Pathology, University Hospital Geneva, Geneva, Switzerland.

Drug Discovery Today
|January 26, 2013
PubMed

Insights

Fibrosis causes organ failure, with myofibroblasts as key cells. Targeting epithelial cells offers a promising new strategy for anti-fibrotic medicines by influencing myofibroblast activation.

Area of Science:

  • Fibrosis research
  • Cellular biology
  • Pharmacological targets

Background:

  • Fibrosis affects millions globally, leading to organ failure.
  • Myofibroblasts are the primary cellular drivers of fibrosis.
  • Existing pharmaceutical targets focus on myofibroblast activation.

Purpose of the Study:

  • To review the hypothesis that epithelial cells can be targeted for anti-fibrotic therapies.
  • To discuss pharmacological targets related to epithelial cell-mediated myofibroblast modulation.

Main Methods:

  • Review of preclinical and clinical evidence.
  • Analysis of the fibrotic microenvironment's role.
  • Exploration of epithelial cell paracrine signaling.

Main Results:

  • The fibrotic microenvironment contains components that activate myofibroblasts.
  • Epithelial cells show potential as a therapeutic target via paracrine action.
  • New pharmaceutical intervention strategies are emerging.

Conclusions:

  • Epithelial cells represent a promising cellular target for anti-fibrotic drug design.
  • Modulating epithelial cell paracrine signaling could inhibit myofibroblast activation.
  • Further research into these targets may yield novel anti-fibrotic medicines.

Related Concept Videos

Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Healing I: Introduction01:11

Healing I: Introduction

Healing is the physiological process by which the body restores the integrity and function of damaged tissues following injury. It involves a coordinated interplay of cellular proliferation, extracellular matrix remodeling, and growth factor signaling. The extent and nature of the tissue damage determine whether healing occurs by resolution, regeneration, or replacement.ResolutionResolution represents the most complete form of healing, occurring when the injury is minimal and tissue...